Please login to the form below

Biosimilars in 2018: EU doctors’ perceptions of RA drug market

Published in pharmaphorum October 2015 by Laurent Chanroux
Physicians in Europe's Big 5 think current market leaders will continue to lead, with biosimilars making the greatest inroads in the field up to 2018, if clearer guidance on efficacy and safety is provided.

A panel of around 200 physicians treating RA across Europe (France, Germany, Italy, Spain and the UK) were asked how they currently treat their patients and what they expect to be doing in 2018. The findings suggest that the market leaders can breathe easy, for the moment at least.

Read the full article here:
www.researchpartnership.com/news/2015/10/article-biosimilars-in-2018-ra-perceptions/




6th January 2016

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

News
Medical Technology specialist joins Research Partnership
Research Partnership
Live webinar
The power of a good story: Turn your insights into effective storytelling with data visualisation
Research Partnership
Article
How will COVID-19 affect uptake of vaccinations against other diseases?
Research Partnership
Podcast
Living With Chronic Illness (Series one)
Research Partnership
Live webinar
China: How pharma can maximize success in this rapidly changing emerging market
Research Partnership
Article
Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma
Research Partnership